

Heart Failure Association of the European Society of Cardiology update on sodium–glucose co-transporter 2 inhibitors in heart failure

Petar M. Seferović^{1,2,*†}, Gabriele Fragasso³, Mark Petrie⁴, Wilfried Mullens^{5,6}, Roberto Ferrari⁷, Thomas Thum⁸, Johann Bauersachs⁹, Stefan D. Anker^{10,11}, Robin Ray¹², Yuksel Çavuşoğlu¹³, Marija Polovina^{1,14}, Marco Metra¹⁵, Giuseppe Ambrosio¹⁶, Krishna Prasad¹⁷, Jelena Seferović^{1,18}, Pardeep S. Jhund¹⁹, Giuseppe Dattilo²⁰, Jelena Čelutkienė²¹, Massimo Piepoli²², Brenda Moura²³, Ovidiu Chioncel^{24,25}, Tuvia Ben Gal²⁶, Stephane Heymans²⁷, Tiny Jaarsma²⁸, Loreena Hill²⁹, Yuri Lopatin³⁰, Alexander R. Lyon³¹, Piotr Ponikowski³², Mitja Lainščak^{33,34}, Ewa Jankowska³², Christian Mueller³⁵, Francesco Cosentino³⁶, Lars H. Lund³⁷, Gerasimos S. Filippatos³⁸, Frank Ruschitzka³⁹, Andrew J.S. Coats⁴⁰, and Giuseppe M.C. Rosano^{41†}

¹Faculty of Medicine, University of Belgrade, Belgrade, Serbia; ²Serbian Academy of Sciences and Arts, Belgrade, Serbia; ³Heart Failure Unit, Clinical Cardiology, University Hospital San Raffaele, Milan, Italy; ⁴Institute of Cardiovascular and Medical Sciences, University of Glasgow, Glasgow, UK; ⁵Faculty of Medicine and Life Sciences, BIOMED - Biomedical Research Institute, Hasselt University, Diepenbeek, Belgium; ⁶Department of Cardiology, Ziekenhuis Oost, Genk, Belgium; ⁷Department of Cardiology and LTTA Centre, University Hospital of Ferrara and Maria Cecilia Hospital, GVM Care and Research, ES Health Science Foundation, Cotignola, Italy; ⁸Hannover Medical School, Institute of Molecular and Translational Therapeutic Strategies, Hannover, Germany; ⁹Department of Cardiology and Angiology, Medical School Hannover, Hannover, Germany; ¹⁰Department of Cardiology (CVK), Berlin Institute of Health Centre for Regenerative Therapies (BCRT), Berlin, Germany; ¹¹German Centre for Cardiovascular Research (DZHK) partner site Berlin, Charité Universitätsmedizin Berlin, Berlin, Germany; ¹²Basildon and Thurrock University Hospitals NHS Foundation Trust, Basildon, UK; ¹³Department of Cardiology, Faculty of Medicine, Eskişehir Osmangazi University, Eskişehir, Turkey; ¹⁴Department of Cardiology, Clinical Centre of Serbia, Belgrade, Serbia; ¹⁵Cardiology, Department of Medical and Surgical Specialties, Radiological Sciences, and Public Health, University of Brescia, Brescia, Italy; ¹⁶Division of Cardiology, University of Perugia, Perugia, Italy; ¹⁷United Kingdom Medicines and Healthcare Products Regulatory Agency, London, UK; ¹⁸Clinic for Endocrinology, Diabetes and Metabolic Disorders, Clinical Centre, Belgrade, Serbia; ¹⁹British Heart Foundation, Cardiovascular Research Centre, University of Glasgow, Glasgow, UK; ²⁰Department of Clinical and Experimental Medicine, University of Messina, Cardiology Unit, Messina, Italy; ²¹Clinic of Cardiac and Vascular Diseases, Institute of Clinical Medicine, Faculty of Medicine, Vilnius University, Vilnius, Lithuania; ²²Heart Failure Unit, Cardiology, G. da Saliceto Hospital, Piacenza, Italy; ²³Hospital das Forças Armadas and CINTESIS - Faculdade de Medicina da Universidade do Porto, Porto, Portugal; ²⁴University of Medicine Carol Davila, Bucharest, Romania; ²⁵Emergency Institute for Cardiovascular Diseases 'Prof. C.C. Iliescu', Bucharest, Romania; ²⁶Department of Cardiology, Rabin Medical Center, Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel; ²⁷Maastricht University Medical Centre, Cardiovascular Research Institute Maastricht, Maastricht, The Netherlands; ²⁸Department of Social and Welfare Studies, Faculty of Health Science, Linköping University, Linköping, Sweden; ²⁹School of Nursing and Midwifery, Queen's University Belfast, Belfast, UK; ³⁰Volgograd State Medical University, Regional Cardiology Centre Volgograd, Volgograd, Russian Federation; ³¹National Heart and Lung Institute, Imperial College London and Royal Brompton Hospital, London, UK; ³²Centre for Heart Diseases, Faculty of Health Sciences, Wrocław Medical University, Wrocław, Poland; ³³Department of Internal Medicine, and Department of Research and Education, General Hospital Murska Sobota, Murska Sobota, Slovenia; ³⁴Faculty of Medicine, University of Ljubljana, Ljubljana, Slovenia; ³⁵Department of Cardiology, Cardiovascular Research Institute Basel, University Hospital Basel, Basel, Switzerland; ³⁶Cardiology Unit, Department of Medicine, Karolinska Institute and Karolinska University Hospital, Stockholm, Sweden; ³⁷Department of Medicine, Karolinska Institutet, and Heart and Vascular Theme, Karolinska University Hospital, Stockholm, Sweden; ³⁸National and Kapodistrian University of Athens, School of Medicine, University Hospital Attikon, Athens, Greece; ³⁹Department of Cardiology, University Heart Center, Zürich, Switzerland; ⁴⁰Pharmacology, Centre of Clinical and Experimental Medicine, IRCCS San Raffaele Pisana, Rome, Italy; and ⁴¹Department of Medical Sciences, IRCCS San Raffaele Pisana, Rome, Italy

Received 9 September 2020; revised 1 October 2020; accepted 10 October 2020; online publish-ahead-of-print 27 October 2020

*Corresponding author. Faculty of Medicine, University of Belgrade, Heart Failure Society of Serbia, 8 Koste Todorovića, 11000 Belgrade, Serbia. Tel/Fax: +381 11 3614738, Email: seferovic.petar@gmail.com

The Heart Failure Association (HFA) of the European Society of Cardiology (ESC) has recently issued a position paper on the role of sodium–glucose co-transporter 2 (SGLT2) inhibitors in heart failure (HF). The present document provides an update of the position paper, based of new clinical trial evidence. Accordingly, the following recommendations are given:

- Canagliflozin, dapagliflozin empagliflozin, or ertugliflozin are recommended for the prevention of HF hospitalization in patients with type 2 diabetes mellitus and established cardiovascular disease or at high cardiovascular risk.
- Dapagliflozin or empagliflozin are recommended to reduce the combined risk of HF hospitalization and cardiovascular death in symptomatic patients with HF and reduced ejection fraction already receiving guideline-directed medical therapy regardless of the presence of type 2 diabetes mellitus.

Keywords

Heart failure • Sodium–glucose co-transporter 2 inhibitors • Type 2 diabetes mellitus • Cardiovascular outcomes • Renal function

The Heart Failure Association (HFA) of the European Society of Cardiology (ESC) has recently issued a position paper on the role of sodium–glucose co-transporter 2 (SGLT2) inhibitors in heart failure (HF).¹ This document was published awaiting the results of ongoing clinical trials that have since become available. Hence, the present document provides an HFA update of the position paper on the role of SGLT2 inhibitors in the prevention and treatment of HF¹ in light of new evidence from clinical trials.

Recently, the VERTIS-CV (Cardiovascular Outcomes with Ertugliflozin in Type 2 Diabetes) trial demonstrated that ertugliflozin vs. placebo reduces the risk of HF hospitalization in patients with type 2 diabetes mellitus (T2DM) and established cardiovascular (CV) disease (23.7% with a history of HF), with a hazard ratio (HR) of 0.70 [95% confidence interval (CI) 0.54–0.90, *P*-value not provided in accordance with the pre-specified hierarchical statistical testing plan].² The benefit was similar in patients with or without a history of HF. These findings are consistent with those of empagliflozin, canagliflozin and dapagliflozin, described in the previous document,¹ and solidify the evidence that SGLT2 inhibitors have a beneficial effect in reducing the risk of hospitalizations for HF in patients with T2DM and CV risk factors or established CV disease.

Furthermore, in 3730 patients with symptomatic HF and reduced ejection fraction (HFrEF), with or without T2DM, the EMPEROR-Reduced trial (Empagliflozin Outcome Trial in Patients With Chronic Heart Failure With Reduced Ejection Fraction) demonstrated a significant risk reduction with empagliflozin 10 mg daily vs. placebo in the primary combined endpoint of CV death or hospitalization for HF (HR 0.75, 95% CI 0.65–0.86; *P* < 0.001) during a median follow-up of 16 months.³ The trial included ~50% of patients without T2DM, 73% had left ventricular ejection fraction <30%, 79% had N-terminal B-type natriuretic peptide level ≥1000 pg/mL and almost a half of patients had significant renal dysfunction at baseline [estimated glomerular filtration rate (eGFR) ≥20 to 60 mL/min/1.73 m²]. The benefit was observed regardless of the presence of T2DM, baseline renal function, or the use of medications for HFrEF treatment, including sacubitril/valsartan (~20% of the trial patients). Risk reduction was primarily driven

by a substantial decrease in HF hospitalizations (HR 0.69, 95% CI 0.59–0.81; *P* < 0.001). The trial has also shown a significant reduction in the two pre-specified secondary outcomes, namely, the total number of HF hospitalizations (first and recurrent events: HR 0.70, 95% CI 0.58–0.85; *P* < 0.001) and a decline in renal function (defined as a mean slope of change in eGFR, mL/min/1.73 m² per year).

A meta-analysis which used study-level data from DAPA-HF (A Study to Evaluate the Effect of Dapagliflozin on the Incidence of Worsening Heart Failure or Cardiovascular Death in Patients With Chronic Heart Failure) and patient-level data from EMPEROR-Reduced further explored the effect of SGLT2 inhibition with dapagliflozin or empagliflozin in a broader spectrum of HF patients from both trials.⁴ The meta-analysis demonstrated a reduction in both CV (HR 0.86, 95% CI 0.76–0.98; *P* = 0.027) and all-cause mortality (HR 0.87, 95% CI 0.77–0.98; *P* = 0.018) with SGLT2 inhibition, without any evidence of a statistical heterogeneity between dapagliflozin and empagliflozin. Similarly, SGLT2 inhibition reduced the risk of the combined endpoint of HF hospitalization or CV death (HR 0.74, 95% CI 0.68–0.82; *P* < 0.0001), as well as the first HF hospitalization (HR 0.69, 95% CI 0.62–0.78; *P* < 0.0001), the total number of HF hospitalizations or CV mortality (HR 0.75, 95% CI 0.68–0.84; *P* < 0.0001) and worsening renal function (HR 0.62, 95% CI 0.43–0.90; *P* = 0.013). The results were consistent in patients with or without T2DM. Data on the safety profile of both agents were reassuring given that no excess risk in adverse events was noted compared with placebo, including renal adverse events, volume depletion, severe hypoglycaemia, bone fractures, amputations or Fournier's gangrene.⁴ In particular, ketoacidosis was uncommon with only three cases in DAPA-HF (all in patients with T2DM) and no cases observed in EMPEROR-Reduced.⁴

In addition, a secondary analysis of the DAPA-CKD trial (A Study to Evaluate the Effect of Dapagliflozin on Renal Outcomes and Cardiovascular Mortality in Patients With Chronic Kidney Disease) in patients with chronic kidney disease (eGFR 25–75 mL/min/1.73 m² and urinary albumin-to-creatinine ratio 200–5000 mg/g) with or without T2DM, revealed a significant risk reduction in hospitalizations for HF or CV death (HR 0.71, 95% CI 0.55–0.92; *P* = 0.0089) with dapagliflozin vs. placebo.⁵

[†]These authors contributed equally to the position paper.

Assessing the landscape for the use of SGLT2 inhibitors in the prevention and treatment of HF, it can be concluded:

- **Canagliflozin, dapagliflozin empagliflozin, or ertugliflozin are recommended for the prevention of HF hospitalization in patients with T2DM and established CV disease or at high CV risk.**
- **Dapagliflozin or empagliflozin are recommended to reduce the combined risk of HF hospitalization and CV death in symptomatic patients with HF_{rEF} already receiving guideline-directed medical therapy regardless of the presence of T2DM.**

Conflict of interest: P.M.S. reports honorarium for lecture from Medtronic, Abbott, Servier, AstraZeneca, Respicardia; consultancy agreement and honorarium for lecture from Boehringer Ingelheim, Novartis; and consultancy agreement from Vifor Pharma. M.P. reports grants and personal fees from AstraZeneca, Novartis, Novo Nordisk, Boehringer Ingelheim, Abbvie, Takeda, Bayer, Pharmacosmos; personal fees from Vifor, Cardioentis, Alnylam, outside the submitted work. R.F. reports personal fees from Servier International, Merck Serono, Pfizer, DOC Generici, Società Prodotti Antibiotici Spa; grants and personal fees from Novartis, outside the submitted work. T.T. reports personal fees and other from Cardior Pharmaceuticals GmbH, outside the submitted work. J.B. reports personal fees from Abbott, AstraZeneca, Bayer, BMS, Boehringer Ingelheim, Daiichi Sankyo, Medtronic, MSD, Novartis, Pfizer, Servier; grants and personal fees from Abiomed, CvRX, Vifor, Zoll, outside the submitted work. M.P. reports honorarium for lecture from Boehringer Ingelheim, outside the submitted work. M.M. reports personal fees from minimal amount honoraria from AstraZeneca, Abbott Vascular, Bayer, Edwards Therapeutics, Vifor Pharma for participation in trials' committees or public speeches, outside the submitted work. J.Č. reports personal fees from AstraZeneca, Boehringer Ingelheim, Novartis, Servier, Amgen, outside the submitted work. L.H. reports personal fees from Novartis, outside the submitted work. A.R.L. reports personal fees from Ferring Pharmaceuticals, Eli Lilly, Bristol Myers Squibb, Eisai Ltd, Myocardial Solutions and Heartfelt Technologies. C.M. reports personal fees from AstraZeneca, Boehringer Ingelheim, outside the submitted work. L.H.L. reports personal fees from Merck, Sanofi, Bayer, Pharmacosmos, Abbott, Medscape, Myokardia; grants and personal fees from Vifor-Fresenius, AstraZeneca, Relypsa, Novartis, Mundipharma, Boehringer Ingelheim; grants from Boston Scientific, outside the submitted work. G.S.F. reports other from Committee Member in trials sponsored by Medtronic, Vifor, Servier, Novartis, BI, outside the submitted work. F.R. since 1 January 2018: no personal payments; all

payments directly to the University of Zurich; before 2018: reports grants and personal fees from SJM/Abbott, Servier, Novartis, Bayer; personal fees from Zoll, AstraZeneca, Sanofi, Amgen, BMS, Pfizer, Fresenius, Vifor, Roche, Cardioentis, Boehringer Ingelheim; other from Heartware, grants from Mars, outside the submitted work. F.C. reports personal fees from Novo Nordisk, MSD, Pfizer, Mundipharma, Lilly, AstraZeneca, BMS, outside the submitted work. A.J.S.C. reports personal fees from AstraZeneca, Bayer, Boehringer Ingelheim, Menarini, Novartis, Nutricia, Servier, Vifor, Actimed, Arena, Cardiac Dimensions, Corvia, CVRx, Enopace, ESN Cleer, Faraday, Gore, Impulse Dynamics, Respicardia, outside the submitted work, S.D.A. reports grants and personal fees from Vifor Int, Abbott Vascular; personal fees from Bayer, Boehringer Ingelheim, Novartis, Servier, Impulse Dynamics, Cardiac Dimensions, outside the submitted work. P.P. reports personal fees and other from Boehringer Ingelheim, AstraZeneca, during the conduct of the study; personal fees and other from Amgen, Novartis, Servier, Bayer, BMS, Vifor Pharma, Renal Guard Solutions, Impulse Dynamics, personal fees from Pfizer, Berlin Chemie, outside the submitted work. B.M. reports personal fees from Boehringer Ingelheim, AstraZeneca, outside the submitted work. M.L. reports personal fees from AstraZeneca, Boehringer Ingelheim, during the conduct of the study. All other authors have nothing to disclose.

References

1. Seferović PM, Fragasso G, Petrie M, Mullens W, Ferrari R, Thum T, Bauersachs J, Anker SD, Ray R, Çavuşoğlu Y, Polovina M, Metra M, Ambrosio G, Prasad K, Seferović J, Jhund PS, Dattilo G, Čelutkienė J, Piepoli M, Moura B, Chioncel O, Ben Gal T, Heymans S, de Boer RA, Jaarsma T, Hill L, Lopatin Y, Lyon AR, Ponikowski P, Lainščák M, Jankowska E, Mueller C, Cosentino F, Lund L, Filippatos GS, Ruschitzka F, Coats AJ, Rosano GM. Sodium-glucose co-transporter 2 inhibitors in heart failure: beyond glycaemic control. A position paper of the Heart Failure Association of the European Society of Cardiology. *Eur J Heart Fail* 2020;**22**:1495–1503.
2. Cannon CP, Pratley R, Dagogo-Jack S, Mancuso J, Huyck S, Masiukiewicz U, Charbonnel B, Frederich R, Gallo S, Cosentino F, Shih WJ, Gantz I, Terra SG, Cherney DZ, McGuire D; VERTIS CV Investigators. Cardiovascular outcomes with ertugliflozin in type 2 diabetes. *N Engl J Med* 2020;**383**:1425–1435.
3. Packer M, Anker SD, Butler J, Filippatos G, Pocock SJ, Carson P, Januzzi J, Verma S, Tsutsui H, Brueckmann M, Jamal W, Kimura K, Schnee J, Zeller C, Cotton D, Bocchi E, Böhm M, Choi DJ, Chopra V, Chuquiere E, Giannetti N, Janssens S, Zhang J, Gonzalez Juanatey JR, Kaul S, Brunner-la Rocca HP, Merkely B, Nicholls SJ, Perrone S, Pina I, Ponikowski P, Sattar N, Senni M, Seronde MF, Spinar J, Squire I, Taddei S, Wanner C, Zannad F; EMPEROR-Reduced Trial Investigators. Cardiovascular and renal outcomes with empagliflozin in heart failure. *N Engl J Med* 2020;**383**:1413–1424.
4. Zannad F, Ferreira JP, Pocock SJ, Anker SD, Butler J, Filippatos G, Brueckmann M, Ofstad AP, Pfarr E, Jamal W, Packer M. SGLT2 inhibitors in patients with heart failure with reduced ejection fraction: a meta-analysis of the EMPEROR-Reduced and DAPA-HF trials. *Lancet* 2020;**396**:819–829.
5. Heerspink HJL, Stefánsson BV, Correa-Rotter R, Chertow GM, Greene T, Hou FF, Mann JFE, McMurray J, Lindberg M, Rossing P, Sjöström CD, Toto RD, Langkilde AM, Wheeler DC; DAPA-CKD Trial Committees and Investigators. Dapagliflozin in patients with chronic kidney disease. *N Engl J Med* 2020;**383**:1436–1446.